Premium
Dopamine‐Induced Antihypertensive Effects and Plasma Insulin Rise Are Blocked by Metoclopramide in Labetalol‐Treated Patients
Author(s) -
Martin Gladys,
Forte Pablo,
Luchsinger Augusta,
Mendoza Freddy,
UrbinaQuintana Adalberto,
Pieretti Otto Hernandez,
Romero Eduardo,
Velasco Manuel
Publication year - 1994
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1994.tb03971.x
Subject(s) - metoclopramide , labetalol , medicine , dopamine , blood pressure , insulin , bolus (digestion) , endocrinology , heart rate , anesthesia , vomiting
Eleven patients with moderate to severe hypertension were studied at the Vargas Hospital of Caracas. The patients were pretreated with labetalol, 800 to 1200 mg/day, orally, over a period of 1 week, after which an intravenous infusion of dopamine, .5 to 3 μg/kg/minute, was given. Two intravenous dopamine infusions (30 minutes each) were performed before and after the injection of metoclopramide (30 mg, intravenous bolus). Two washout periods were also included before and after metoclopramide administration. Dopamine induced a decrease of blood pressure from 171.9 + 6.35/103.6 ± 3.12 to 152.7 ± 7.55/93.8 ± 2.97 mm Hg (P < .001) without altering heart rate, and it increased plasma insulin levels from 8.29 ± .70 μU/mL to 12.09 ± 1.83 μU/mL (P < .01). Metoclopramide caused no changes of blood pressure or plasma insulin levels. Hypotensive responses and plasma insulin increases due to dopamine were blocked by metoclopramide, however. The authors conclude that a dopaminergic receptor may be involved in some cardiovascular responses and in modulating insulin secretion in humans.